Commercial-scale viral vector manufacture: Technical challenges & strategic implications

In by

Sponsored by:
Pall Biotech

Following recent mainstream media coverage of reported supply and demand mismatch, viral vectors now dominate much of the discussion within the cell and gene therapy sector. This On Demand panel webinar provides insight from three leading experts at the forefront of vector manufacturing, as they share their first-hand experiences in moving to commercial-scale manufacture of viral vectors including:

  • Current approaches to commercial-scale manufacture of viral vectors and the unique challenges/limitations of each.
  • Real world experience of the different upstream and downstream processes and their impact on yield, efficiency, safety, cost of goods.
  • Potential impact of vector manufacturing decisions on your business model and clinical development timeline.

Hear from our panel of industry experts:

  • Dr Michael Kelly, Director, Asset Leadership, Gene Therapy, Biogen
  • Dr Clive Glover, Senior Global Marketing Manager, Cell & Gene Therapy, Pall Life Sciences
  • Dr Richard Snyder, Chief Scientific Officer, Brammer Bio
Fields marked with an * are required

Are you actively using virus to develop a therapy at this time?

Are you currently evaluating technologies for viral vector manufacturing?

What type of virus are you using?

Would you like to receive more information about Pall’s products and services, and related products and services from Pall’s related companies?

By clicking the Submit button below and proceeding I confirm that I have reviewed and agree with the Terms of Use and the Privacy Policy.

By registering to view this On Demand Webinar you are also signing up as a member of Cell & Gene Therapy Insights and agree to be contacted by our sponsors. We will email you a username and password so you can read all our open access content.


Dr Michael Kelly

Director, Asset Leadership, Gene Therapy, Biogen, USA
Mike Kelly Biogen
Dr. Mike Kelly has over 20 years of experience in the field of gene therapy. During this time, Mike has been responsible for various aspects of research, development and clinical manufacturing for a number of lentiviral, adenoviral and Adeno-associated virus (AAV) -based therapeutics. Currently, Mike works at Biogen, where he is a Director in the Asset Development and Portfolio Management group, leading the gene therapy portfolio. Prior to his current role, Mike was the Director of Gene Therapy Development at Genzyme Corporation, where he was responsible for process development and manufacturing for Genzyme's gene therapy programs. Prior to that, Mike was most recently the Site Director at Genzyme’s development and clinical manufacturing facility in San Diego. Before joining Genzyme, Mike worked at Cell Genesys and Somatix Therapy Corporation, where he held various roles in research and development and clinical manufacturing for gene therapy programs.

Dr Clive Glover

Senior Global Marketing Manager, Cell & Gene Therapy, Pall Corporation, UKClive Glover
Clive leads Pall’s cell and gene therapy business. Previously he was responsible for driving product development efforts around cell therapy at GE Healthcare and has also held positions in marketing and product management at STEMCELL Technologies. Clive holds a PhD in Genetics from the University of British Columbia.

Dr Richard Snyder

Chief Scientific Officer, Brammer Bio., USARichard Snyder
Dr. Snyder was the founder of Florida Biologix, which was spun out of the University of Florida in 2015 and merged to create Brammer Bio in 2016. Dr. Snyder has been investigating virus biology, vector development, cGMP manufacturing and analytical technologies, and viral vector-mediated gene transfer for over 30 years, and was a member of teams who developed novel viral vector-based human gene therapies. Dr. Snyder was an Associate Professor of Molecular Genetics and Microbiology, and Director of Biotherapeutic Programs at the University of Florida; an Assistant Professor of Pediatrics at Harvard Medical School; and was previously employed by Cell Genesys, Somatix, Merlin, and Avigen where he was engaged in the development of gene transfer vector and vaccine technology, along with therapeutic applications. Dr. Snyder was a postdoctoral fellow at Johns Hopkins University School of Medicine, received his doctoral degree in Microbiology from The State University of New York at Stony Brook, and obtained his B.A. in Biology from Washington University in St. Louis.